Flexion Therapeutics Inc (NASDAQ:FLXN) has been given a $40.00 target price by Cantor Fitzgerald in a research report issued on Monday. The firm presently has a “buy” rating on the specialty pharmaceutical company’s stock. Cantor Fitzgerald’s target price points to a potential upside of 104.19% from the company’s current price.

Other research analysts have also issued reports about the company. Royal Bank of Canada set a $44.00 target price on Flexion Therapeutics and gave the company a “buy” rating in a report on Sunday, March 26th. Zacks Investment Research lowered Flexion Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, May 9th. Janney Montgomery Scott reiterated a “buy” rating and issued a $30.00 target price on shares of Flexion Therapeutics in a report on Saturday, March 11th. Wells Fargo & Co reiterated an “outperform” rating and issued a $30.00 target price on shares of Flexion Therapeutics in a report on Saturday, March 25th. Finally, BMO Capital Markets reiterated a “positive” rating and issued a $33.00 target price on shares of Flexion Therapeutics in a report on Tuesday, February 7th. One equities research analyst has rated the stock with a sell rating, seven have given a buy rating and two have assigned a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $29.23.

Analyst Recommendations for Flexion Therapeutics (NASDAQ:FLXN)

Flexion Therapeutics (NASDAQ:FLXN) traded up 2.08% on Monday, hitting $19.59. The stock had a trading volume of 982,188 shares. Flexion Therapeutics has a 52-week low of $10.60 and a 52-week high of $29.41. The company’s market cap is $622.12 million. The firm’s 50-day moving average is $22.71 and its 200-day moving average is $20.56.

Flexion Therapeutics (NASDAQ:FLXN) last released its earnings results on Thursday, May 4th. The specialty pharmaceutical company reported ($0.75) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.73) by $0.02. Equities research analysts anticipate that Flexion Therapeutics will post ($3.72) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Flexion Therapeutics Inc (FLXN) Given a $40.00 Price Target at Cantor Fitzgerald” was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/05/23/flexion-therapeutics-inc-flxn-given-a-40-00-price-target-at-cantor-fitzgerald-2.html.

In other news, insider Neil Bodick sold 5,000 shares of Flexion Therapeutics stock in a transaction dated Friday, March 17th. The stock was sold at an average price of $20.41, for a total transaction of $102,050.00. Following the sale, the insider now owns 50,937 shares in the company, valued at $1,039,624.17. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Frederick W. Driscoll sold 3,000 shares of Flexion Therapeutics stock in a transaction dated Thursday, March 23rd. The stock was sold at an average price of $23.00, for a total value of $69,000.00. Following the sale, the chief financial officer now owns 10,777 shares in the company, valued at approximately $247,871. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 18,000 shares of company stock worth $407,950. 18.00% of the stock is owned by insiders.

Hedge funds have recently bought and sold shares of the company. State Street Corp boosted its stake in Flexion Therapeutics by 111.8% in the first quarter. State Street Corp now owns 829,254 shares of the specialty pharmaceutical company’s stock worth $22,316,000 after buying an additional 437,648 shares during the period. Kingdon Capital Management L.L.C. boosted its stake in Flexion Therapeutics by 29.2% in the fourth quarter. Kingdon Capital Management L.L.C. now owns 1,379,486 shares of the specialty pharmaceutical company’s stock worth $26,238,000 after buying an additional 311,865 shares during the period. Novo A S boosted its stake in Flexion Therapeutics by 27.3% in the fourth quarter. Novo A S now owns 1,397,718 shares of the specialty pharmaceutical company’s stock worth $26,585,000 after buying an additional 300,000 shares during the period. Pictet Asset Management Ltd. purchased a new stake in Flexion Therapeutics during the first quarter worth approximately $7,323,000. Finally, Alyeska Investment Group L.P. purchased a new stake in Flexion Therapeutics during the fourth quarter worth approximately $4,755,000. Institutional investors and hedge funds own 62.25% of the company’s stock.

About Flexion Therapeutics

Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.

12 Month Chart for NASDAQ:FLXN

Receive News & Ratings for Flexion Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.